Astex Pharmaceuticals Inc  

(Public, NASDAQ:SUPG)   Watch this stock  
Find more results for SUPG
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E 0.00
Div/yield     -
EPS 0.04
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '13) 2012
Net profit margin -25.18% 9.92%
Operating margin -42.80% -8.48%
EBITD margin - 10.35%
Return on average assets -6.35% 2.99%
Return on average equity -7.20% 3.61%
Employees 136 -
CDP Score - -


Suite 200, 4140 Dublin Blvd.
DUBLIN, CA 94568
United States - Map
+1-925-5600100 (Phone)
+1-925-5600101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Astex Pharmaceuticals, Inc., formerly SuperGen, Inc. is a pharmaceutical company. The Company is primarily engaged in the discovery and development of small molecule therapeutics with a focus on oncology and hematology. The Company is developing a pipeline of medicines for partnership with pharmaceutical companies. It is also engaged in the application of fragment-based drug discovery and development of small-molecule therapeutics. Using its fragment-based drug discovery platform, Pyramid, Astex Therapeutics Limited, a wholly owned subsidiary, has built a pipeline of molecularly-targeted drugs for large pharmaceutical partners and internal development that are at various stages of clinical, pre-clinical and early discovery development. In October 2013, Otsuka Holdings Co Ltd announced that its wholly owned subsidiary, Otsuka Pharmaceutical Co., Ltd completed, through its wholly owned indirect subsidiary Autumn Acquisition Corporation, its acquisition of Astex Pharmaceuticals, Inc.